Literature DB >> 3121749

A double monoclonal IgG1 kappa and IgG2 kappa in a single myeloma patient. Variation in clonal products and therapeutic responses.

F Goñi1, J Chuba, J Buxbaum, B Frangione.   

Abstract

Two electrophoretically homogeneous immunoglobulins were detected in the serum of a patient with multiple myeloma. The heavy chains were of different classes (gamma 1 and gamma 2). The light chains of both were kappa, but had different electrophoretic mobilities on polyacrylamide gels. Amino acid sequence analysis, carbohydrate determinations, and biosynthetic experiments indicated that the difference seen in their electrophoretic mobility was due to the glycosylation of one but not the other kappa-chain. The primary structure of both chains demonstrated that they both used a V kappa 1 and a J kappa 2 gene segment and the same C kappa allele, Km(1,2), and that both contained the same junctional three amino acid deletion. However, they varied by 19 amino acids in the first 94 amino terminal residues encoded for by the V kappa gene, with some of the substitutions requiring two base changes in the appropriate codons. Moreover, the malignant "clones" producing the two proteins differed in their responses to chemotherapy. These data indicate that, although the two clones producing the serum proteins were different at the time of study, they may have arisen from the same precursor clone.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3121749

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  2 in total

1.  Light chain deposition disease derived from the kappa I light chain subgroup. Biochemical characterization.

Authors:  M M Picken; B Frangione; B Barlogie; M Luna; G Gallo
Journal:  Am J Pathol       Date:  1989-04       Impact factor: 4.307

2.  Molecular analysis of immunoglobulin genes reveals frequent clonal relatedness in double monoclonal gammopathies.

Authors:  R C Tschumper; A Dispenzieri; R S Abraham; K J Henderson; D F Jelinek
Journal:  Blood Cancer J       Date:  2013-04-19       Impact factor: 11.037

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.